Key result
Switching to clopidogrel matches continued aspirin for ulcer healing at 8 weeks.
Why the study?
The gastrotoxicity of clopidogrel in patients with active aspirin-induced peptic ulcer disease was unknown.
Does clopidogrel plus omeprazole improve ulcer healing compared to aspirin plus omeprazole in patients with aspirin-induced peptic ulcer disease?
RCT (n=129)
Single-blind
randomized
Does clopidogrel plus omeprazole improve ulcer healing compared to aspirin plus omeprazole in patients with aspirin-induced peptic ulcer disease?
In patients with aspirin-associated peptic ulcer disease of low to moderate grade, both early conversion to clopidogrel and continuation of aspirin (both with omeprazole) result in similarly high rates of ulcer healing.
Answers are grounded in this paper and cite their sources.
Supports continuing aspirin plus PPI without mandatory switch; confirms equivalent healing to clopidogrel in this RCT.
BACKGROUND: Clopidogrel causes significantly less symptomatic peptic ulcer disease and gastrointestinal bleeding than low-dose aspirin in average-risk patients. The gastrotoxicity of clopidogrel in patients with active peptic ulcer disease is unknown. AIM: To compare the incidence of unhealed ulcers in patients receiving clopidogrel or aspirin. METHODS: Patients with aspirin-induced peptic ulcer disease treated with omeprazole (20 mg/day) were randomized to receive clopidogrel (75 mg/day) or to continue with low-dose aspirin. Success was defined as ulcer/erosion healing at the eighth week. RESULTS: One hundred and twenty-nine patients were recruited (69 received clopidogrel and 60 continued with aspirin). Thirty-one (45%) in the clopidogrel group and 25 (42%) in the aspirin group had a minor gastrointestinal bleed. No ulcer showed an adherent clot or visible vessel. The distributions of peptic ulcer disease were similar in the clopidogrel and aspirin groups (gastric ulcer: 41% vs. 40%; duodenal ulcer: 10% vs. 12%; gastric ulcer + duodenal ulcer: 6% vs. 3%; gastritis: 32% vs. 37%; duodenitis: 4% vs. 7%; gastritis + duodenitis: 0% vs. 2%). Clopidogrel and aspirin were re-started after 0.86 +/- 1.79 and 0.44 +/- 1.60 days, respectively (P = 0.170). Three (4%) patients stopped clopidogrel due to drug rash. Using per protocol analysis, the treatment success rates of clopidogrel and aspirin were 94% (62/66) and 95% (57/60), respectively. CONCLUSIONS: In patients with aspirin-associated peptic ulcer disease of low to moderate grade, both early conversion from aspirin to clopidogrel and continuation of aspirin are safe.
No takes yet. Share an insight, caveat, or question.
Ng et al. (2004) conducted an RCT in aspirin-induced peptic ulcer disease (n=129). Clopidogrel vs. low-dose aspirin was evaluated on ulcer/erosion healing at the eighth week. In patients with aspirin-induced peptic ulcer disease, early conversion to clopidogrel resulted in a 94% ulcer healing rate at 8 weeks, compared to 95% with continued low-dose aspirin.
Synapse has enriched 10 related papers. Consider them for comparative context: